Financial Projections - Preliminary revenue for full year 2024 is expected to be between 10.67billionand10.70 billion, with a net loss projected between (378)millionand(355) million[6]. - Adjusted EBITDA for full year 2024 is anticipated to be between 520millionand525 million, with adjusted EPS ranging from 1.50to1.53[6]. - Cash provided by operating activities for full year 2024 is expected to be between 160millionand165 million[6]. - Gross capital expenditures for full year 2024 are projected to be between 228millionand233 million[6]. Debt Management - The company plans to raise additional debt to finance the acquisition of Rotech Healthcare Holdings, expected to close in the first half of 2025[3]. - Total debt is projected to be between 1.854billionand1.859 billion, with net debt between 1.805billionand1.810 billion[6]. - The company reduced total debt by over 240millionduring2024despitesignificantreinvestmentinthebusiness[4].SegmentPerformance−ThePatientDirectsegmentshowedsolidmid−singledigitgrowthforthefullyear2024,withevenhighergrowthinkeycategories[4].ImpairmentCharges−Anon−cashgoodwillimpairmentchargeofapproximately310 million is expected, impacting net loss per share by about $(4.00)[7]. Upcoming Events - The investor conference call for the fourth quarter and full year 2024 results is scheduled for February 28, 2025[9].